Seroprevalence of Hepatitis B and C in Type 2 Diabetic Patients

Chen, Hua-Fen; Li, Chung‐Yi; Chen, Peter; Shu, Tingting; Lee, Hsinyu

doi:10.1016/s1726-4901(09)70195-9

Cited by 78 publications

(74 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, we cannot establish the diabetic population as a group at high risk for HCV infection. Our findings did not confirm other studies that have reported increased HCV seroprevalence in patients with diabetes [10,[22][23][24][25][26] . In a case-control study conducted in the USA, 4.2% of 594 patients in a cohort with diabetes were found to be infected with HCV compared with 1.6% of control patients (377 patients with thyroid diseases) [27] .…”

Section: Discussioncontrasting

confidence: 99%

Association of hepatitis C virus infection and diabetes in central Tunisia

Kaabia¹,

Jazia²,

Slim³

et al. 2009

WJG

View full text Add to dashboard Cite

AIM:To investigate hepatitis C virus (HCV) seropreva lence in Tunisian patients with diabetes mellitus and in a control group. METHODS:A crosssectional study was conducted to determine the HCV seroprevalence in 1269 patients with diabetes (452 male, 817 female) and 1315 non diabetic patients, attending health centers in Sousse, Tunisia. HCV screening was performed in both groups using a fourthgeneration enzyme immunoassay. RESULTS:In the diabetic group, 17 (1.3%) were found to be HCVinfected compared with eight (0.6%) in the control group, although the difference was not significant (P = 0.057). Quantitative PCR was performed in 20 patients. Eleven patients were positive and showed HCV genotype 1b in all cases. CONCLUSION:Frequency of HCV antibodies was low in patients with diabetes and in the control group in central Tunisia, with no significant difference between the groups.

show abstract

Section: Discussioncontrasting

confidence: 99%

Association of hepatitis C virus infection and diabetes in central Tunisia

Kaabia¹,

Jazia²,

Slim³

et al. 2009

WJG

View full text Add to dashboard Cite

show abstract

“…29 Nonalcoholic steatohepatits, a severe form of nonalcoholic fatty liver disease is regarded as an entity that can progress to cirrhosis 29 as well as primary liver cancers. 30,31 Moreover, type 2 diabetes is a risk factor of hepatitis C, 32 which can also progress to cirrhosis and hepatocellular carcinoma. 33 Additionally, type 2 diabetes has been found to be associated with insulin resistance, compensatory hyperinsulinemia 9,11 and elevated level of insulin-like growth factor, 11 which may interact with liver cells to stimulate mitogenesis and carcinogenesis.…”

Section: Discussionmentioning

confidence: 99%

Risk of Malignant Neoplasms of Liver and Biliary Tract in Diabetic Patients With Different Age and Sex Stratifications

Chen

2010

Hepatology

Self Cite

View full text Add to dashboard Cite

We prospectively investigated 615,532 diabetic patients and 614,871 age-matched and sexmatched control subjects selected from National Health Insurance claims for malignant neoplasms of liver and biliary tract (International Statistical Classification of Diseases and Related Health Problems, 9th edition, codes 155 and 156, respectively) between 2000 and 2006. The person-year approach with Poisson assumption was used to estimate the hazard rates. We also evaluated the age-specific and sex-specific relative risks of these two malignancies in relation to diabetes with Cox proportional hazard regression model with adjustment for potential confounders. The overall hazard rate of malignant neoplasm of the liver was 32.76 and 17.41 per 10,000 patient-years, respectively, for diabetic men and women; the corresponding figures for biliary tract neoplasm were much lower at 1.42 and 1.60 per 10,000 patient-years. Compared with control subjects, diabetic patients had a two-fold increased risk of malignant neoplasm of the liver, but this risk was attenuated by adjusting for selected clinical risk factors (hazard ratio [HR] 1.21; 95% confidence interval [CI] 1.17-1.25). Additionally, diabetic patients were associated with increased risk of biliary neoplasms with an approximate magnitude of 20%-30%, but the HR was attenuated and became insignificant after adjustment for clinical risk factors (HR 1.07; 95% CI 0.95-1.21). Diabetic patients with cirrhosis had the highest relative risk of liver neoplasm (HR 85.25;), whereas those with cholangitis had the highest risk of biliary tract neoplasm (HR 70.30;) compared with control subjects without any clinical risk factors. Conclusion: This population-based study confirms the association of diabetes with liver neoplasm and suggests that diabetic patients with certain clinical risk factors should be educated for strict adherence of liver neoplasm screening. (HEPATOLOGY 2010;52:155-163)

show abstract

“…measuring the prevalence of HCV markers among populations of diabetic patients [8,15,[25][26][27][28][29][30][31][32][33] . Most controlled studies have suggested a significant association, the proportion of HCV-positive persons among diabetics being two-to seven-fold compared to controls [8,15,29,32] . The prevalence of HCV markers among patients with T2D reported by uncontrolled studies was also claimed to be higher than that observed in the general population taken as a reference [25,27,30] .…”

Section: Association Between Hcv and T2dmentioning

confidence: 99%

Hepatitis C virus and type 2 diabetes

Negro¹,

Alaei²

2009

WJG

144

118

View full text Add to dashboard Cite

This review focuses on the relationship between h e p a t i t i s C v i r u s ( H C V ) i n fe c t i o n a n d g l u c o s e metabolism derangements. Cross-sectional and longitudinal studies have shown that the chronic HCV infection is associated with an increased risk of developing insulin resistance (IR) and type 2 diabetes (T2D). The direct effect of HCV on the insulin signaling has been analyzed in experimental models. Although currently available data should be considered as preliminary, HCV seems to affect glucose metabolism via mechanisms that involve cellular pathways that have been implicated in the host innate immune response. IR and T2D not only accelerate the histological and clinical progression of chronic hepatitis C, but also reduce the early and sustained virological response to interferonalpha-based therapy. Thus, a detailed knowledge of the mechanisms underlying the HCV-associated glucose metabolism derangements is warranted, in order to improve the clinical management of chronic hepatitis C patients.

show abstract

Seroprevalence of Hepatitis B and C in Type 2 Diabetic Patients

Abstract: The rate of seropositive anti-HCV is 2.8 times higher in type 2 DM patients than non-diabetic control subjects.

Cited by 78 publications

References 35 publications

Association of hepatitis C virus infection and diabetes in central Tunisia

Association of hepatitis C virus infection and diabetes in central Tunisia

Risk of Malignant Neoplasms of Liver and Biliary Tract in Diabetic Patients With Different Age and Sex Stratifications

Hepatitis C virus and type 2 diabetes

Contact Info

Product

Resources

About